• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In-vitro evaluation of antifungal agents in the treatment of yeast peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD).

作者信息

Edwards R, Birrell L N, Finch R G

出版信息

Chemioterapia. 1987 Feb;6(1):3-7.

PMID:3829134
Abstract

This study compared the static and kinetic activities of six antifungal agents, in broth and used dialysate, against six yeast strains known to have caused peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD). Minimum inhibitory concentrations (MIC) and IC50 results show a trend towards greater activity by amphotericin B, 5-fluorocytosine, tioconazole and itraconazole in comparison to miconazole and ketoconazole although there was some strain variability. Minimum fungicidal concentrations (MFCs) of amphotericin B were less than or equal to 1mg/l, while 5-fluorocytosine and the azoles showed large discrepancies between MIC and MFC values. In kinetic studies amphotericin B was the most potent fungicidal agent. 5-fluorocytosine showed modest activity and failed to achieve total killing. The azoles demonstrated variable degrees of inhibition of C. glabrata and showed minimal activity with C. albicans. Itraconazole showed good activity against C. parapsilosis in broth. All agents, with the exception of 5-fluorocytosine, showed reduced activity in used dialysate in comparison to broth.

摘要

相似文献

1
In-vitro evaluation of antifungal agents in the treatment of yeast peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD).
Chemioterapia. 1987 Feb;6(1):3-7.
2
Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment.真菌性腹膜炎并发腹膜透析:27例报告及治疗综述
Q J Med. 1989 May;71(265):407-16.
3
Flucytosine-miconazole treatment of Candida peritonitis. Its use during continuous ambulatory peritoneal dialysis.氟胞嘧啶-咪康唑治疗念珠菌性腹膜炎。其在持续性非卧床腹膜透析中的应用。
Arch Intern Med. 1982 Mar;142(3):577-8.
4
Non Candida albicans fungal peritonitis in continuous ambulatory peritoneal dialysis patients.持续性非卧床腹膜透析患者的非白色念珠菌真菌性腹膜炎
Adv Perit Dial. 2001;17:176-9.
5
Candida peritonitis in children on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患儿的念珠菌性腹膜炎
Int J Pediatr Nephrol. 1982 Dec;3(4):287-91.
6
Successful treatment of fungal peritonitis with intracatheter antifungal retention.导管内抗真菌保留治疗真菌性腹膜炎成功
Adv Perit Dial. 1995;11:172-5.
7
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.抗真菌药物对致病性阴道酵母菌分离株的体外比较活性
J Med Vet Mycol. 1994;32(4):267-74.
8
Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients.从非艾滋病患者咽喉部分离出的白色念珠菌菌株对5-氟胞嘧啶、咪康唑和两性霉素B的敏感性
Rev Latinoam Microbiol. 2002 Apr-Jun;44(2):65-8.
9
[Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration].[从侵袭性真菌病中分离出的念珠菌属的鉴定及抗真菌药敏性。生长抑制百分比对确定最低抑菌浓度的影响]
Rev Med Chil. 2002 Apr;130(4):416-23.
10
In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.使用Etest对念珠菌和曲霉属进行伏立康唑及其他抗真菌药物的体外药敏试验:一项法国多中心研究的结果
Int J Antimicrob Agents. 2005 Apr;25(4):321-8. doi: 10.1016/j.ijantimicag.2004.11.010.

引用本文的文献

1
Fatal Hormonema dematioides peritonitis in a patient on continuous ambulatory peritoneal dialysis: criteria for organism identification and review of other known fungal etiologic agents.一名持续非卧床腹膜透析患者发生致命性皮炎外瓶霉腹膜炎:病原体鉴定标准及其他已知真菌病原体回顾
J Clin Microbiol. 1998 Jul;36(7):2157-63. doi: 10.1128/JCM.36.7.2157-2163.1998.